Karbis

Candesartan cilexetil, the active ingredient in Karbis, is a Angiotensin II receptor blocker (ARB) presented as an oral dosage form for oral use. It is employed to lower blood pressure and to manage heart failure and diabetic kidney disease in adult patients.

GNH USA supplies Karbis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Karbis (candesartan cilexetil) acts on the renin‑angiotensin system to control cardiovascular and renal conditions.

- Hypertension: reduces systolic and diastolic blood pressure, helping to prevent cardiovascular events. - Heart failure: improves symptoms and reduces the risk of hospitalization by decreasing cardiac afterload. - Diabetic nephropathy: slows progression of renal impairment by lowering intraglomerular pressure.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Dizziness: feeling light‑headed, especially after standing. - Headache: mild to moderate pain in the head region. - Fatigue: unusual tiredness or lack of energy. - Upper respiratory tract infection: symptoms such as sore throat or nasal congestion.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue, or throat that may compromise breathing. - Hyperkalemia: elevated blood potassium levels that can affect heart rhythm. - Renal dysfunction: worsening kidney function indicated by rising creatinine or reduced glomerular filtration rate.

Before initiating therapy, clinicians should assess individual risk factors and monitor relevant parameters. - Blood pressure monitoring: check regularly to ensure therapeutic response and avoid hypotension. - Renal function assessment: evaluate serum creatinine and eGFR at baseline and during treatment. - Electrolyte surveillance: monitor serum potassium, especially when combined with potassium‑sparing agents. - Pregnancy caution: avoid use in pregnancy due to potential fetal toxicity (Category D). - Storage at room temperature: keep in the original container, protect from moisture and direct sunlight.

Candesartan cilexetil may interact with several drug classes; some combinations require avoidance while others need close observation.

Major Interactions (Avoid): - Aliskiren in diabetic patients: combined use can increase risk of renal impairment and hyperkalemia. - Potassium‑sparing diuretics (e.g., spironolactone): may cause dangerous elevations in serum potassium. - ACE inhibitors: concurrent therapy heightens the chance of hyperkalemia and renal dysfunction. - NSAIDs (high‑dose or chronic): can reduce antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - Lithium: candesartan may increase lithium levels, requiring serum monitoring. - Other antihypertensives (beta‑blockers, calcium channel blockers): may enhance blood pressure lowering, necessitating dose adjustments. - Diuretics (thiazides, loop diuretics): may affect electrolyte balance and renal function, warranting periodic labs.